plasma-derived FVIII/VWF concentrate

DRUG2 trials

Sponsors

Grifols Therapeutics LLC, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Conditions

Hemophilia AVon Willebrand Disease

Phase 4

Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease

WithdrawnNCT02472665

Grifols Therapeutics LLCVon Willebrand Disease

Start: 2013-12-01End: 2024-12-10Updated: 2026-05-22

Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients

Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoHemophilia A

Start: 2015-01-31End: 2020-01-31Target: 20Updated: 2015-06-23